Homologous recombination status drives disease-free survival in patients with advanced ovarian cancer undergoing hyperthermic intraperitoneal chemotherapy at the time of interval debulking surgery.

ABSTRACT:

Objective

Describe surgical outcomes of patients undergoing HIPEC with cisplatin (C) alone or cisplatin/paclitaxel (CP), compared to interval debulking surgery (IDS) without HIPEC, and stratify disease-free survival (DFS) by treatment and homologous recombination (HR) status.

Methods

Retrospective chart review of patients with advanced ovarian cancer undergoing IDS with and without HIPEC between 2018-2024. DFS was compared using a log rank test. Cox proportional hazards model was used to test association between treatment group and recurrence.

Results

74 patients were included: 20 in no HIPEC, 28 in HIPEC-C, and 26 in HIPEC-CP groups. Duration of surgery was shortest in no HIPEC group (159 ± 64 min vs HIPEC-C 377 ± 54 min vs HIPEC-CP 400 ± 48 min, p < 0.

SUBMITTER: Levytska K 

PROVIDER: S-EPMC12641191 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature